1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Competitor Analysis: Antibody-Drug Conjugates (ADC)

Competitor Analysis: Antibody-Drug Conjugates (ADC)

  • April 2013
  • -
  • La Merie Publishing
  • -
  • 104 pages

Product description

The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.

The report includes a compilation of currently active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Antibody-Drug Conjugates (ADC)
Table of Contents

Adcetris Pipeline
Antibody-Drug Conjugates with Auristatin Derivatives
Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives
Kadcyla Pipeline
Antibody-Drug Conjugates with Maytansinoid Derivatives
Antibody-Drug Conjugates with Irinotecan Derivatives
Antibody-Drug Conjugates with Doxorubicin
Antibody-Drug Conjugates with Calicheamicin Derivatives
Antibody-Drug Conjugates with Duocarmycin Derivative
Antibody-Drug Conjugates with Various Drugs
Antibody-Drug Conjugates with Not Disclosed Drugs
Other Immunoconjugates
Antibody-Drug Conjugates: RandD Collaboration Agreements
Antibody-Drug Conjugates: Licensing Agreements About La Merie
Corporate ADC RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6 650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 7 125

Bladder Cancer: Analytical Tool

August 2016 $ 7 125

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Australia - Forecast

  • September 2016
    13 pages
  • Cancer  

  • Australia  

View report >

Cancer Statistics in the US

  • September 2016
    16 pages
  • Cancer  

    Cardiovascular ...  

    Occupational He...  

View report >

Skin Cancer Statistics in New Zealand

  • September 2016
    26 pages
  • Skin Cancer  

    Cancer  

    Spray Tanning  

  • New Zealand  

    Australia  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.